Similar companies
Income Statement (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Revenue | 1.6M | 31200% |
| Gross Profit | 1.6M | 1150.7% |
| Operating expense | 22M | 27.5% |
| Net Income | -26M | 32.2% |
| EBITDA | -25M | 34.1% |
Balance Sheet (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Total Assets | 196M | 22.8% |
| Total Liabilities | 44M | 1.6% |
| Total Equity | 152M | 30.7% |
| Shares Outstanding | 176M | 10.1% |
Cash Flow (USD)
| Q1 '25 | QoQ | |
|---|---|---|
| Cash from operations | -18M | 26.6% |
| Cash from financing | 60M | 38604.5% |
EPS
Financial Highlights for ATAI Life Sciences in Q1 '25
ATAI Life Sciences reported a revenue of 1.6M, which is a 31200% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 1.6M, marking a 1150.7% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Operating Expenses for this period were 22M, showing a -27.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -26M, showing a 32.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -25M, showing a 34.1% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for ATAI Life Sciences with growth in revenue, gross profit, and net income.
